Macquarie Group Ltd. increased its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 64.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 18,664 shares of the biotechnology company’s stock after purchasing an additional 7,289 shares during the quarter. Macquarie Group Ltd.’s holdings in bluebird bio were worth $2,564,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BLUE. QS Investors LLC increased its position in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares during the last quarter. Bank of Montreal Can increased its position in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC bought a new position in shares of bluebird bio during the 2nd quarter valued at approximately $184,000. SG Americas Securities LLC increased its position in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. bought a new position in shares of bluebird bio during the 2nd quarter valued at approximately $210,000.
In other bluebird bio news, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $125.73, for a total value of $616,077.00. Following the completion of the sale, the insider now directly owns 32,205 shares in the company, valued at approximately $4,049,134.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Nick Leschly sold 2,127 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $145.17, for a total value of $308,776.59. Following the completion of the sale, the chief executive officer now owns 257,486 shares of the company’s stock, valued at $37,379,242.62. The disclosure for this sale can be found here. Insiders sold a total of 106,918 shares of company stock valued at $15,181,462 over the last quarter. Company insiders own 3.90% of the company’s stock.
A number of equities analysts recently issued reports on the company. Maxim Group boosted their price objective on bluebird bio from $170.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, November 30th. SunTrust Banks boosted their price objective on bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Jefferies Group restated a “hold” rating and set a $130.00 price objective on shares of bluebird bio in a report on Friday, November 3rd. Morgan Stanley upgraded bluebird bio from an “underweight” rating to an “equal weight” rating in a report on Friday, November 3rd. Finally, Barclays boosted their price objective on bluebird bio from $151.00 to $162.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $134.35.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at $162.30 on Tuesday. bluebird bio, Inc. has a 1-year low of $60.95 and a 1-year high of $174.65.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the prior year, the company posted ($2.07) earnings per share. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. analysts predict that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
WARNING: “Macquarie Group Ltd. Has $2.56 Million Stake in bluebird bio, Inc. (BLUE)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/macquarie-group-ltd-has-2-56-million-stake-in-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.